Navigation Links
VirtualScopics Achieves Operating Cash Flow Breakeven in the Fourth Quarter 2008; Reports Record 2008 Revenue and Gross Profit
Date:2/25/2009

v. These include without limitation: the risk of cancellation or delay of customer contracts or specifically as it relates to contact awards, the risk that they may not get signed. Other risks include the company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others. All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

(1) Operating cash flow breakeven = Operating loss less depreciation, amortization and stock compensation expense

-Financial tables to follow-

                         VirtualScopics, Inc. and Subsidiary
                       Consolidated Statements of Operations

                             For the Three Months       For the Year Ended
                               Ended December 31,           December 31,
                              2008         2007         2008         2007
                            (unaudited)  (unaudited)  (unaudited)

    Revenues                $1,947,501   $1,462,336   $7,130,518   $5,647,049
    Cost of services           973,979      948,975    4,031,198,   3,680,409
          Gross profit         973,522      513,361    3,099,320    1,966,640

    Operating expenses
      Research and
       development             243,553      315,706      941,193    1,440,312
      Sales and marketing      282,854      193,546    1,219,882      749,329
      General and
       administrative          446,054      580,490    2,035,077    2,268,668
      Stock-based
       compensation expense    199,392      443,428    1,123,283    1,484,884
      Depreciation and
       amortization            115,584      122,642      466,149      485,520
          Total operating
           expenses       
'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Nasdaq Grants VirtualScopics Request for Continued Listing
2. VirtualScopics Schedules Fourth Quarter 2008 Earnings Announcement
3. Pharsight Achieves First License Sale for Public-Source Database
4. GenoLogics Geneus Achieves GeneChip-compatible(TM) Status with the Affymetrix GeneChip(R) Microarray Platform
5. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
6. Signalife Achieves $1.98 Million Sales Orders Thus Far
7. Diplomat Specialty Pharmacy Health Services Division Achieves High Marks in Pilot Program for Chronic Kidney Disease Management
8. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
9. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
10. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
11. NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Lexington,Kentucky and Queens, New York (PRWEB) October 02, ... is pleased to announce funding received to ... pathway in Alzheimer’s disease. A grant award from ... Institute on Aging (NIA), National Institutes of Health ... as Novel AD Therapeutics." The company also received ...
(Date:10/2/2014)... Arbor, Mich. (PRWEB) October 02, 2014 ... working with Hile Creative to refine its marketing approach. ... — MS Bioworks serves researchers in the biological sciences, ... MS Bioworks has already seen substantial growth over the ... engage with current customers, the company plans to launch ...
(Date:10/2/2014)... Schlieren, Switzerland and Morgantown, West Virginia (PRWEB) October ... Inc. (OTCQB: PRGB ) and InSphero AG jointly ... on mass spectrometry imaging of InSphero’s 3D InSight™ ... InSphero and hosted members of InSphero’s scientific team ... of the microtissues. Protea has since developed workflows ...
(Date:10/2/2014)... October 02, 2014 At a time when ... Products has introduced a new kind of squeeze aimed ... is the Scienceware® Squeeze Rite™ Wash Bottle , catalog ... position within the bottle reduces the waste of reagents, solutions ... those liquids. , “Easier to squeeze when compared to standard ...
Breaking Biology Technology:Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3Hile Creative to Provide Copywriting and Graphic Design Services for MS Bioworks 2Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 2Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 3Protea Biosciences and InSphero AG Successful in Mass Spectrometry Imaging of 3D Microtissues 4New Wash Bottle Reduces Waste of Reagents, Solutions, and Other Liquids 2
... Reportlinker.com announces that a new market research ... Orthopedic Biomaterials, The World Market ... products, which can be organic or synthetic in ... fracture to facilitate healing or to compensate for ...
... 3, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer today announced the presentation of clinical ... platinum-resistant ovarian cancer patients.   The data were presented ... A. Matulonis, medical director of gynecologic oncology at Dana-Farber ...
... 3, 2011 Asmacure Ltee, a clinical-stage ... agonists for the treatment of asthma and other inflammatory ... as chief executive officer.  With a solid foundation established ... it progresses its lead compound, a potential new treatment ...
Cached Biology Technology:Reportlinker Adds Orthopedic Biomaterials, The World Market 2Reportlinker Adds Orthopedic Biomaterials, The World Market 3Reportlinker Adds Orthopedic Biomaterials, The World Market 4EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 2EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 3EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 4Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3
(Date:9/30/2014)... on Earth, but when the climate changes and temperatures ... The amount of time needed to adjust to new ... in the future, reveals a new study from researchers ... journal Proceedings of the Royal Society B . ... of greenhouse gases in the atmosphere. The greenhouse effect ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... criminals, requires evidence and witnesses; but on the scale ... easier said than done. A team of ... Arizona State University may soon change that. Under a ... a new way to close the gaps in the ...
... Sarasota FL., December 17, 2007 Researchers at ... of the EASE (Exhale Airway Stents for Emphysema) Trial, ... treatment that may offer a significant new, minimally-invasive option ... focuses on a procedure called airway bypass that involves ...
... latest American Chemical Society (ACS) News Service Weekly PressPac with ... News.,Please credit the individual journal or the American Chemical Society ... FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is embargoed for ... ARTICLE #1 FOR IMMEDIATE RELEASE A faster, ...
Cached Biology News:ASU researchers use NASA satellites to improve pollution modeling 2Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema 2American Chemical Society's Weekly PressPac -- Dec. 12, 2007 2American Chemical Society's Weekly PressPac -- Dec. 12, 2007 3American Chemical Society's Weekly PressPac -- Dec. 12, 2007 4American Chemical Society's Weekly PressPac -- Dec. 12, 2007 5American Chemical Society's Weekly PressPac -- Dec. 12, 2007 6American Chemical Society's Weekly PressPac -- Dec. 12, 2007 7American Chemical Society's Weekly PressPac -- Dec. 12, 2007 8American Chemical Society's Weekly PressPac -- Dec. 12, 2007 9American Chemical Society's Weekly PressPac -- Dec. 12, 2007 10
For demonstration of Helicobacter pylori...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
... is used in conjunction with your existing apoptosis ... apoptosis according to your existing procedure (also reserve ... control). Once you have induced apoptosis in your ... population and incubate the cells for an additional ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: